Glioblastoma is the most lethal brain tumor. The poor prognosis results from lack of defined tumor margins, critical location of the tumor mass and presence of chemo- and radio-resistant tumor stem cells. The current treatment for glioblastoma consists of neurosurgery, followed by radiotherapy and temozolomide chemotherapy. A better understanding of the role of molecular and genetic heterogeneity in glioblastoma pathogenesis allowed the design of novel targeted therapies. New targets include different key-role signaling molecules and specifically altered pathways. The new approaches include interference through small molecules or monoclonal antibodies and RNA-based strategies mediated by siRNA, antisense oligonucleotides and ribozymes. Most of these treatments are still being tested yet they stay as solid promises for a clinically relevant success.
Molecular targets in glioblastoma / Zorzan, Maira; Giordan, Enrico; Redaelli, Marco; Caretta, Antonio; Mucignat-Caretta, Carla. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:9(2015), pp. 1407-1420. [10.2217/fon.15.22]
|Appare nelle tipologie:||1.1 Articolo su rivista|